Pembrolizumab plus chemotherapy for patients with metastatic triple-negative breast cancer

Bookmark and Share
Published: 27 May 2020
Views: 700
Rating:
Save
Dr Javier Cortés - IOB Institute of Oncology, Madrid and Barcelona, Spain

Dr Javier Cortés speaks to ecancer online about the KEYNOTE-355 trial he presented at the virtual ASCO 2020 meeting.

The KEYNOTE-355 trial investigates pembrolizumab in combination with chemotherapy as first-line treatment in patients with metastatic triple-negative breast cancer (mTNBC).

Dr Cortés explains the results and how the continues to evolve.

Read more information here.